Last reviewed · How we verify
NCT06368414: AsterA
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Phase 2 trial testing Asciminib in Chronic Myeloid Leukemia, Chronic Phase in 69 participants. Currently enrolling.
31 August 2028
Quick facts
| Lead sponsor | Korean Society of Hematology |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 11 March 2024 |
| Primary completion | 31 August 2028 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Asciminib (ASCIMINIB) — full drug profile →
Conditions studied
- Chronic Myeloid Leukemia, Chronic Phase — all drugs for Chronic Myeloid Leukemia, Chronic Phase →
Sponsor
Korean Society of Hematology
Who can join
19 and older, any sex, with Chronic Myeloid Leukemia, Chronic Phase. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06368414
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Asciminib
Trials testing the same drug.
- NCT07040982 — Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymph · Phase 1 · not yet recruiting
- NCT07039760 — Asciminib With or Without Sildenafil for Brain Tumors · EARLY_PHASE1 · not yet recruiting
- NCT06629584 — Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia · Phase 2 · recruiting
- NCT06427811 — Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients · Phase 4 · completed
- NCT06308588 — Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acut · Phase 1, PHASE2 · recruiting
Other recruiting trials for Chronic Myeloid Leukemia, Chronic Phase
Currently open trials in the same condition.
- NCT06163430 — A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participa · Phase 1, PHASE2 · recruiting
- NCT06119269 — Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase · recruiting
- NCT06233890 — The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia · active not recruiting
- NCT03722420 — Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) · Phase 3 · active not recruiting
- NCT03459534 — A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06368414 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korean Society of Hematology
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06368414.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing